Traynor Capital Management Inc. raised its position in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 14.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,799 shares of the company’s stock after buying an additional 2,799 shares during the period. Traynor Capital Management Inc.’s holdings in TherapeuticsMD were worth $123,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Managed Account Services Inc. boosted its position in shares of TherapeuticsMD by 5.5% in the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after buying an additional 1,000 shares during the last quarter. Greenwood Capital Associates LLC boosted its position in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of TherapeuticsMD by 3.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 103,048 shares of the company’s stock worth $742,000 after buying an additional 3,472 shares during the last quarter. American International Group Inc. boosted its position in shares of TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of TherapeuticsMD by 3.5% in the second quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after buying an additional 6,232 shares during the last quarter.

TherapeuticsMD Inc (TXMD) opened at 5.66 on Friday. The company’s market capitalization is $1.15 billion. The stock has a 50 day moving average price of $5.43 and a 200-day moving average price of $5.53. TherapeuticsMD Inc has a 52 week low of $3.50 and a 52 week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. The company had revenue of $4.25 million during the quarter, compared to analyst estimates of $4.91 million. During the same period in the previous year, the business earned ($0.11) earnings per share. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. On average, equities analysts predict that TherapeuticsMD Inc will post ($0.41) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “TherapeuticsMD Inc (NASDAQ:TXMD) Shares Bought by Traynor Capital Management Inc.” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/therapeuticsmd-inc-nasdaqtxmd-shares-bought-by-traynor-capital-management-inc.html.

A number of brokerages have recently commented on TXMD. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a research note on Friday. Deutsche Bank AG set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research note on Friday. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Thursday. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research note on Friday, July 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD has an average rating of “Buy” and a consensus target price of $16.14.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.